anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Conservative therapy is a viable option for patients with chronic subdural hematoma (cSDH) who express no, or only mild symptoms. It is not clear which factors are associated with success of conservative therapy. This study aims to determine conservative therapy's success rate and to identify features possibly associated with success.
METHODS: A monocenter retrospective cohort study, including cSDH patients treated conservatively (wait-and-watch) from 2012 to 2022, was performed. The primary outcome was success of conservative therapy, defined as 'no crossover to surgery' during the follow-up period. Secondary outcomes were (1) factors associated with success, analyzed with univariate and multivariable logistic regression analyses, (2) 30-day mortality (3) time to crossover and (4) reasons for crossover.
RESULTS: We included 159 patients. Conservative therapy was successful in 96 (60%) patients. Hematoma volume (OR 0.79, 95% CI 0.69-0.92) and hypodense hematoma type (OR 3.57, 95% 1.38-9.23) were associated with success. Thirty-day mortality rate was 5% and the median duration between diagnosis and surgery was 19 days (IQR 8-39). Clinical deterioration was the most frequent reason for crossover (in 61/63 patients, 97%) and was accompanied by radiological hematoma progression in 42 patients (67%).
CONCLUSION: In this selected group of patients, conservative therapy was successful in 60%. Smaller hematoma volume and hypodense hematoma type were associated with success. As time until crossover was approximately three weeks, deploying conservative therapy as primary treatment seems safe and could be rewarding as surgical complications can be avoided. Improvement in patient selection in future cohorts remains warranted.
This invention relates to methods for detecting and quantitating a heteroplasmic mutation at position 12027 of mitochondrial DNA in various human tissues. The mutation is a <I>t</I>  T  <I>c</I> substitution that changes the protein structure of NADH-Ubiquinone reductase causing oxidative stress by increased superoxide production and reduced electron transfer. The mutant form predominates in 24% of the mtDNA in lymphocytes from normals and in 47% of a sample of 180 schizophrenics. Several other illnesses such as cancer, cardiovascular disorder and age related neurological, ophthalmological and dermatological age related degeneration are also associated with oxidative stress. The invention thus affords methods of predicting the likelihood of schizophrenia and other ailments before the onset of clinical symptoms. Also disclosed are methods of alleviating the illnesses caused by the mutation by replacing mtDNA or preventing its expression and methods of using quercetin and its glycosides to reduce superoxide emission without compromising the energy transfer capabilities of the reductase.
Evidence suggests that insulin resistance plays an important role in developing diabetes complications. The association between insulin resistance and pain perception is less well understood. This study aimed to investigate the effects of peripheral insulin deficiency on pain pathways in the brain. Diabetes was induced in 60 male rats with streptozotocin (STZ). Insulin was injected into the left ventricle of the brain by intracerebroventricular (ICV) injection, then pain was induced by subcutaneous injection of 2.5% formalin. Samples were collected at 4 weeks after STZ injection. Dopamine (DA), serotonin, reactive oxygen species (ROS), and mitochondrial glutathione (mGSH) were measured by ELISA, and gene factors were assessed by RT-qPCR. In diabetic rats, the levels of DA, serotonin, and mGSH decreased in the nuclei of the thalamus, raphe magnus, and periaqueductal gray, and the levels of ROS increased. In addition, the levels of expression of the neuron-specific enolase and receptor for advanced glycation end genes increased, but the expression of glial fibrillary acidic protein expression was reduced. These results support the findings that insulin has an analgesic effect in non-diabetic rats, as demonstrated by the formalin test. ICV injection of insulin reduces pain sensation, but this was not observed in diabetic rats, which may be due to cell damage ameliorated by insulin.
PURPOSE:To provide a universal medicine capable of efficiently producing IgA in the living body of human and a mammal without a side effect. CONSTITUTION:This invention is an IgA production promoter singly composed of a peptide selected from a group of a peptide mixture obtained by hydrolysis of a lactoferrin, a peptide isolated therefrom and having sequence no. 1 to 30, a chamically synthesized peptide having sequence no. 1 to 31, their pharmaceutically permissible salts and their mixtures or that composed of the above- mentioned peptide and viable cells of a microorganism belonging to Bifidobacterium. This promoter can surely promote production of IgA in the living body of human or a mammal. The IgA production in the living body can be certainly promoted with any of microorganisms so far as the microorgnanism belongs to Bifidobaterium. In addition, this promoter can be administrated with no side effect.
Participants in this arm will be provided a 6 week regimen of exercise videos for their anterior knee pain. Following each exercise session, the participant will be asked for their input concerning each exercise. The algorithm will adjust the exercise regimen for the next session based on the participants input. A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety.
Group 30 CDR \> 0. There will be collection of CSF and blood. The participants will either be labeled by intravenous infusion method with leucine or oral method based off the results from the Young Normal Control Group. They will have 5 lumbar punctures (LPs) and the amount of labeled tau in the CSF will be analyzed to obtain tau kinetics in human central nervous system (CNS).
BACKGROUND AND AIM: The regular uptake of a high-fat diet (HFD) with changing lifestyle causes atherosclerosis leading to cardiovascular diseases and autonomic dysfunction. Therefore, the current study aimed to investigate the correlation of autonomic activity to lipid and atherosclerosis markers. Further, the study proposes a support vector machine (SVM) based model in the prediction of atherosclerosis severity.
METHODS AND RESULTS: The Lead-II electrocardiogram and blood markers were measured from both the control and the experiment subjects each week for nine consecutive weeks. The time-domain heart rate variability (HRV) parameters were derived, and the significance level was tested using a one-way Analysis of Variance. The correlation analysis was performed to determine the relation between autonomic parameters and lipid and atherosclerosis markers. The statistically significant time-domain values were used as features of the SVM. The observed results demonstrated the reduced time domain HRV parameters with the increase in lipid and atherosclerosis index markers with the progressive atherosclerosis severity. The correlation analysis revealed a negative association between time-domain HRV parameters with lipid and atherosclerosis parameters. The percentage accuracy increases from 86.58% to 98.71% with the increase in atherosclerosis severity with regular consumption of HFD.
CONCLUSIONS: Atherosclerosis causes autonomic dysfunction with reduced HRV. The negative correlation between autonomic parameters and lipid profile and atherosclerosis indexes marker revealed the potential role of vagal activity in the prognosis of atherosclerosis progression. The support vector machine presented a respectable accuracy in the prediction of atherosclerosis severity from the control group.
Trauma Informed-Mindfulness-Based Relapse Prevention (TI-MBRP) will be a 4-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT) into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance abuse, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events.
PURPOSE: A pharmaceutical composition containing an essential oil of Chrysanthemum boreale as an effective ingredient is provided. The extract of Chrysanthemum boreale shows excellent inhibiting activity against pathogenic bacteria and fungal microorganisms and is thus used as an antibacterial agent and/or antifungal agent. CONSTITUTION: An antibacterial agent and/or antifungal composition contain an extract of Chrysanthemum boreale and a pharmaceutically acceptable carrier or excipient. The extract of Chrysanthemum boreale is obtained by a steam distillation method. The desirable dose of the extract is in the range of 0.3 to 1,000mg/kg body weight. The composition has excellent growth inhibiting effect on causative agents of gingivitis, dental caries, gastrointestinal disease and major infections.
BACKGROUND: Glycative stress, characterized by the formation and accumulation of advanced glycation end products (AGEs) associated with protein glycation reactions, has been implicated in inducing a decline of muscle function. Although the inverse correlation between glycative stress and muscle mass and strength has been demonstrated, the underlying molecular mechanisms are not fully understood. This study aimed to elucidate how glycative stress affects the skeletal muscle, particularly the adaptive muscle response to hypertrophic stimuli and its molecular mechanism.
METHODS: Male C57BL/6NCr mice were randomly divided into the following two groups: the bovine serum albumin (BSA)-treated and AGE-treated groups. Mice in the AGE-treated group were intraperitoneally administered AGEs (0.5 mg/g) once daily, whereas those in the BSA-treated group received an equal amount of BSA (0.5 mg/g) as the vehicle control. After 7 days of continuous administration, the right leg plantaris muscle of mice in each group underwent functional overload treatment by synergist ablation for 7 days to induce muscle hypertrophy. In in vitro studies, cultured C2C12 myocytes were treated with AGEs (1 mg/mL) to examine cell adhesion and cell membrane permeability.
RESULTS: Continuous AGE administration increased the levels of fluorescent AGEs, Nε-(carboxymethyl) lysine, and methylglyoxal-derived hydroimidazolone-1 in both plasma and skeletal muscle. Plantaris muscle weight, muscle fibre cross-sectional area, protein synthesis rate, and the number of myonuclei increased with functional overload in both groups; however, the increase was significantly reduced by AGE treatment. Some muscles of AGE-treated mice were destroyed by functional overload. Proteomic analysis was performed to explore the mechanisms of muscle hypertrophy suppression and myofibre destruction by AGEs. When principal component analysis was performed on 4659 data obtained by proteomic analysis, AGE treatment was observed to affect protein expression only in functionally overloaded muscles. Enrichment analysis of the 436 proteins extracted using the K-means method further identified a group of proteins involved in cell adhesion. Consistent with this finding, dystrophin-glycoprotein complex proteins and cell adhesion-related proteins were confirmed to increase with functional overload; however, this was attenuated by AGE treatment. Additionally, the treatment of C2C12 muscle cells with AGEs inhibited their ability to adhere and increased cell membrane permeability.
CONCLUSIONS: This study indicates that glycative stress may be a novel pathogenic factor in skeletal muscle dysfunctions by causing loss of membrane integrity and preventing muscle mass gain.
Disclosed are methods and compositions for facilitating entry of compounds to cells. In some forms, the compositions comprise one or more aminoglycosides and one or more lipids. The disclosed compositions can also comprise one or more compounds or compositions. It was discovered that the disclosed compositions increase the efficiency of delivery of compounds into cells. The disclosed compositions and methods increase both delivery into cells and the activity of compounds once delivered into cells. For example, the disclosed methods and compositions can be used to deliver nucleic acids to cells and to thereby increase the activity of such nucleic acids delivered to cells. The disclosed compositions can be used to deliver compounds and compositions to cells in vitro, ex vivo and in vivo. Delivery can be, for example, non-specific, non-directed, non-targeted, specific, directed or targeted.
NEW MATERIAL:A compound expressed by formula I (R<1> and R<2> are H or 1-3C alkyl), acid addition salt thereof and alkali salt thereof. EXAMPLE:5,6-Dihydro-1,2-dioxo-4H-pyroro[3,2,1-ij] guinoline-8-acetic acid ethyl ester. USE:An antirheumatic agent exhibiting no cyclooxygenase inhibiting action and being also excellent in safety and having bone breakage suppressing action. PREPARATION:A novel compound expressed by formula II (R is H or 1-3C lower alkyl) is hydrolyzed and as necessary subjected to decarbonylation in the presence of an oxidizing agent (e.g. hydrogen peroxide solution or peracetic acid) to provide the compound expressed by formula I. The reaction is preferably carried out at 0-50 deg.C for 30min-3hr.
Long-term use of sevoflurane, an inhalation anesthetic, could negatively impact cognitive function. Current studies have suggested that cognitive impairment induced by sevoflurane may be associated with neuroinflammation. Sestrin2 (SESN2), which belongs to a family of stress-inducible genes, has been reported to exert neuroprotective effects against brain injury. However, its role and underlying mechanisms in sevoflurane-induced cognitive dysfunction in aged rats remain unknown. A sevoflurane-induced aging rat injury model with or without SESN2 overexpression was constructed. The learning and memory abilities of rats were evaluated by the MWM test. ELISA assay and qRT-PCR were conducted to analyze the level of pro-inflammatory factors in the hippocampus. Levels of oxidative stress markers were measured by DHE staining or kit methods. Neuronal apoptosis in the hippocampus was detected using TUNEL assay. Expression of proteins were analyzed by western blot. Sevoflurane exposure caused elevated protein level of SESN2 in hippocampus and cognitive impairment of aged rats. Importantly, overexpression of SESN2 alleviated sevoflurane-induced cognitive dysfunction and inhibited the production of pro-inflammatory factors, oxidative stress, and neuronal apoptosis in the hippocampus. Furthermore, SESN2 overexpression suppressed NLRP3 inflammasome activation induced by sevoflurane. These findings suggested that SESN2 could exert neuroprotective against sevoflurane-induced nerve injury of aged rats through anti-oxidant and anti-inflammatory effects.
The invention discloses preparation and applications of preparations which can be taken as both food and medicine, and can be used for treating cancer. It is found by research that patient blood pollution, immune function deterioration, and tumor forming are caused by cancer. Cancer is caused by cytometaplasia of histocytes of patients into cancer cells because of survival of the fittest, so that continuous survival of the histocytes is realized, and cancer is a new developed parasitic species. Treatment of cancer must follow biological heredity and variation rules; treatment should be started from blood pollution treatment, improvement of the whole functional imbalance, and improvement of immune function deterioration. Natural food and wild food which can be used for treating diseases are fully used so as to treat root causes; human body detoxifying functions are activated, blood is purified, the source of cancer cells is eliminated, and blood regeneration is promoted. At the same time, cancer cell hyperfunction is inhibited, tumor proliferation is stopped, the whole function balance is adjusted, and foundation is provided for complete treatment of cancer.
Physical training is well known to support a healthy lifestyle. Patients with asthma are often unnecessarily restricted of physical activities or avoid exercise due to the unpleasant experience of exercise-induced dyspnea. As a consequence both children and adults with asthma are less fit than their peers. Like in healthy individuals, regular training supports health in asthmatics. In short-term training programs improvements of physical capabilities have been achieved in children and young adults with asthma. Programs of longer durations than 3 months have not been published in controlled trials. Effects of exercise training on quality of life in adult asthmatics are lacking.
Thirty participants with treatment-resistant late life depression (TR-LLD) will attend 5 instructional days of Sudarshan Kriya Yoga (SKY), followed by 3 weekly follow-ups, and 8 weeks of bimonthly follow-ups. Participants will also practice SKY for 25 minutes per day at home. These participants will attend 4 mental health assessments at weeks 0, 4, 8, and 12. Thirteen of the recruited TR-LLD will attend an MRI at baseline and post-intervention.
FIELD: medicine. ^ SUBSTANCE: group of inventions refers to medicine, namely to dentistry. Offered is a method of mineralising a dental enamel involving contacting the dental enamel or a dental damage with a protein-solubilising, protein-destroying or protein-hydrolysing agent preceding contacting the dental enamel with phosphopeptide-stabilised amorphous calcium phosphate (ACP) or amorphous calcium fluoride phosphate (ACFP). Preferentially, phosphopeptide is casein phosphopeptide (CPP). The protein-solubilising, protein-destroying or protein-hydrolysing agent is chosen from one or more substances of the group consisting of a bleaching agent, a detergent, a chaotropic agent, protease or mixed proteases. Preferentially, the bleaching agent such as sodium hypochlorite or carbamide peroxide is used. Also, offered are methods of mineralising hypomineralised dental enamel damages caused by caries, fluorosis, dental erosion and a therapeutic kit for treatment and prevention of said conditions, including: a) the protein-solubilising, protein-destroying or protein-hydrolysing agent and b) a CPP-ACP or CPP-ACFP complex in a pharmaceutically acceptable carrier. ^ EFFECT: attained effective reconditioning of a missing mineral in the dental enamel with hypomineralised damages. ^ 10 cl, 2 tbl
FIELD: pharmacology, pharmacy. SUBSTANCE: invention relates to a liquid, aqueous pharmaceutical suspension preparation. The preparation comprises amoxicillin trihydrate and potassium clavulanate as active components and effective amount of cellulose as a natural vehicle and possibly additional excipients. Invention provides preparing effective stable pharmaceutical preparation with pleasant taste and reduced gastroenteric intolerance. EFFECT: valuable properties of preparation. 9 cl, 2 tbl, 2 ex
The invention relates to a traditional Chinese medicine preparation for treating pharyngitis. The traditional Chinese medicine preparation is prepared by raw materials with a formula A and raw materials with a formula B. The formula A comprises 30 g of reed rhizome, 10 g of schizonepetae herba, 10 g of radix sileris, 10 g of periostracum cicadae, 10 g of stiff silkworm, 10 g of radix platycodi, 10 g of licorice roots, 30 g of rhizoma pinellinae praeparata and 30 g of fresh ginger. The formula B comprises 30 g of salviae miltiorrhizae, 10 g of myrrh, 10 g of frankincense, 10 g of angelica sinensis and 30 g of gypsum. The formula A and the formula B are decocted with water respectively. The traditional Chinese medicine preparation is taken twice every day, one in the morning and the other at night, with the formula A being taken first and then the formula B being taken. The traditional Chinese medicine preparation has the functions of clearing heat to promote salivation, dispelling wind and relieving exterior syndrome, removing dampness to relieve pains, relieving sore throat and ventilating lung, removing dampness to reduce phlegm, removing stasis to relieve pains, cooling the blood and resolving swelling, eliminating phlegm, cultivating qi and disperse swelling to settle pains, can achieve the objects of clearing the lung to purge intense heat and relieving pharyngeal pains, and has the characteristics of definite curative effect, convenient use and low cost. A curative rate is 91.5% and an effective rate is 100%.
Niraparib is an orally available, highly selective poly (adenosine diphosphate \[ADP\]-ribose) polymerase (PARP) inhibitor, with potent activity against PARP-1 and PARP-2 deoxyribonucleic acid (DNA)-repair polymerases. AA is a pro-drug of abiraterone which selectively inhibits the enzyme 17 alpha-hydroxylase/C17,20-lyase (CYP17), that is found in the testes and adrenals (leading to systemic inhibition of testosterone production), as well as in prostate tissues and tumors. The rationale of the study is to investigate the various strengths and formulations of niraparib and AA plus prednisone or prednisolone (P) in metastatic castration resistant prostate cancer (mCRPC) participants with and without homologous recombination repair (HRR) gene alterations. In participants with metastatic prostate cancer, DNA-repair anomalies are found in approximately 15 percent (%) to 20% of tumors. This study consists 4 periods: screening phase (up to 21 days); treatment phase (up to 22 days); extension and long-term extension phases (from day 23 until discontinuation); and post-treatment follow up phase (end of treatment \[EoT\] visit within 30 days after the last dose of study treatment). Total duration of study is up to 1.4 years. Efficacy, safety, pharmacokinetics (PK), and biomarkers will be assessed at specified time points during this study. Participants safety will be monitored throughout the study.
Restenosis of peripheral artery lesions remains a challenging problem to overcome after percutaneous revascularization of atherosclerotic disease in the femoropopliteal arterial system. Rates of restenosis are as high as 60% after a year. Treatment options include medical therapy, angioplasty, arthrectomy and stent placement. The heterogeneity of disease between patients, variable length of target lesions and presence of unpredictable physical forces requires individualized treatment plans.

Vascular response to injury appears to play an important role in the development of restenosis. IL-1α is a potent inflammatory cytokine that plays a central role in vascular inflammation and vascular smooth muscle proliferation--both in acute and chronic injury. CV-18C3 antagonizes the biologic activity of IL-1α and is theorized to prevent the early IL-1α mediated inflammation that leads to vascular smooth muscle hypertrophy and restenosis, as well as the late IL-1α mediated atherosclerotic plaque formation.